company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2862000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2862000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2862000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2257000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6510000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8767000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5905000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,21000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,21000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5884000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,26000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5858000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5858000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5858000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1200000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-4.85
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1200000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-4.85
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1207000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 06:08:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-4.85
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2975000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2975000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2975000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2392000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7930000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10322000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7347000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,15000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7332000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,285000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7047000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7047000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7047000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1200000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-5.73
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1200000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-5.73
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1229000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 16:07:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-5.73
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3549000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3549000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3549000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2386000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8585000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10971000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7422000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,13000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7409000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,135000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7274000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7274000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7274000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1200000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-5.82
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1200000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-5.82
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1250000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 09:36:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-5.82
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3482000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3482000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3482000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2607000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8193000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7318000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,7000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7311000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,77000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7234000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7234000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7234000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,2600000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.74
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,2600000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.74
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,2637000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q3,2013-07-01,2013-09-30,2014-11-12 07:30:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.74
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3785000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3785000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3785000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3042000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8077000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11119000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7334000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,487000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,514000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6820000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-497000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7317000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7317000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7317000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,5523000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,9.06
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,5523000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,9.06
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,5500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,9.06
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3546000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3546000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3546000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3280000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8926000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12206000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8660000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,36000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,36000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8624000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-20000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8644000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8644000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8644000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,18800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,18800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.46
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,18841000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q1,2014-01-01,2014-03-31,2015-05-14 06:08:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4981000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4981000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4981000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3024000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11873000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14897000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9916000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,55000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,55000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9861000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-5000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9866000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9866000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9866000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21400000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21400000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.46
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21465000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 08:00:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6059000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6059000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6059000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3360000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9803000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13163000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7104000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,57000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,57000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7047000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-41000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7088000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7088000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7088000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.33
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.33
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21521000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 06:04:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.33
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4645000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4645000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4645000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3968000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12571000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16539000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11894000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,62000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-60000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11892000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,66000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11826000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11826000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11826000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20865000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20865000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20900000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4287000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4287000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4287000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4220000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11211000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15431000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11144000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,108000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,108000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11036000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11036000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11036000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11036000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25100000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.44
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25100000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.44
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25072000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 06:04:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.44
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6315000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6315000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6315000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4596000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13310000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17906000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11591000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,117000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,117000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11474000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11474000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11474000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11474000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.45
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.45
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25690000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 06:11:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.45
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5858000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5858000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5858000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5213000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,24720000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29933000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24075000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,104000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,104000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23971000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23971000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23971000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23971000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.93
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.93
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25825000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 06:04:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.93
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,363341000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,363341000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,363341000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8602000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20956000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29558000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,333783000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,158000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,155000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,333938000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,37810000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,296128000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,296128000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,296128000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25661000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,11.55
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27035000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,11.05
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25700000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,11.55
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6520000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6520000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6520000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8057000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18856000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26913000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20393000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,536000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,536000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19857000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6817000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13040000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13040000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13040000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26600000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26600000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.49
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26351000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q1,2016-01-01,2016-03-31,2017-05-05 06:05:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9229000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9229000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9229000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8106000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22177000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30283000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21054000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,646000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,646000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20408000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-7271000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13137000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13137000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13137000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.49
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26800000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.49
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26924000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:17:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.49
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6680000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6680000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6680000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9146000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23890000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33036000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26356000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,639000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,639000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25717000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6303000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19414000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19414000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19414000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27000000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.72
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27000000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.72
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27139000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q3,2016-07-01,2016-09-30,2017-11-06 16:25:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.72
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8262000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8262000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8262000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10522000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29149000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39671000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-31409000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,646000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,646000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30763000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-10657000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20106000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20106000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20106000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26955000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.74
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26955000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.74
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26955000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.74
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10135000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10135000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10135000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10486000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33760000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,44246000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-34111000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,668000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,668000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33443000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33443000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33443000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33443000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27600000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.21
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27600000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.21
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27657000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q1,2017-01-01,2017-03-31,2018-05-08 16:18:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.21
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7822000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7822000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7822000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9363000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,41744000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,51107000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43285000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,702000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,702000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-42583000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1703000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-44286000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44286000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-44286000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28000000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.58
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28000000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.58
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27946000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:16:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.58
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8333000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8333000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8333000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9674000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,42733000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,52407000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-44074000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,792000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,792000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-43282000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-43282000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-43282000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-43282000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28100000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.54
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28100000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.54
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28020000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:18:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.54
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13218000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13218000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13218000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10479000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,32671000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,43150000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29932000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,816000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-94000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,722000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-29210000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-29211000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-29211000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-29211000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27945000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.05
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27945000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.05
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27945000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.05
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,32486000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,32486000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,32486000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10478000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,43552000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54030000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21544000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1159000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1154000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20390000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20390000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20390000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20390000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,32400000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.63
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,32400000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.63
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,32314000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:31:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.63
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7580000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7580000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7580000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9782000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33380000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,43162000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35582000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1522000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1522000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-34060000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34060000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34060000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-34060000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34400000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.99
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34400000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.99
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34401000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q2,2018-04-01,2018-06-30,2019-08-07 20:48:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.99
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5771000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5771000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5771000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9832000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,44687000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54519000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-48748000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1531000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1504000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-47244000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-47244000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-47244000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-47244000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.37
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34500000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.37
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34482000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q3,2018-07-01,2018-09-30,2019-11-06 17:16:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.37
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4031000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4031000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4031000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9579000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34733000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,44312000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-40281000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1580000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-52000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1528000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-38753000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-38753000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-38753000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38753000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33976000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.14
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33976000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.14
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33976000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.14
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5347000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5347000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5347000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10510000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,31753000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,42263000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-36916000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1533000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1531000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-35385000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35385000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35385000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-35385000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34700000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.02
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34700000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.02
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34794000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:19:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.02
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3333000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3333000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3333000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9661000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29425000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39086000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35753000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1363000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1362000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-34391000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34391000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34391000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-34391000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34700000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.99
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34700000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.99
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34909000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 20:48:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.99
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2984000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2984000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2984000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13206000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26948000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40154000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-37170000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1100000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1101000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-36069000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36069000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36069000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-36069000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35000000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.03
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35000000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.03
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34996000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q3,2019-07-01,2019-09-30,2019-11-06 17:16:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.03
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3210000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3210000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3210000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9372000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25937000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35309000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32099000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,744000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,742000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-31357000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-31357000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-31357000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-31357000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34970000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.88
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,34970000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.88
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34970000.0
Five Prime Therapeutics Inc,FPRX,549300Z652HXXGMB7V71,0001175505,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.88
